

# iViCT 2019

International Virtual Conference on Theranostics



4–5 September 2019  
#iViCT2019

## AGENDA

Wednesday, 4 September 2019

### OPENING I

IAEA Coordinator: Diana Paez  
Masters of Ceremony: Sugitha Sureshkumar

Time (CEST)	Title	Speaker	Affiliation	Location	Learning Objectives
09:20-09:30	Welcome Remarks	Najat Mokhtar-DDG NA May Abdel-Wahab-DIR NAHU	International Atomic Energy Agency	In Vienna	
09:30-09:40	Conference Introduction	Diana Paez-SH NMDI	International Atomic Energy Agency	In Vienna	

### Session I-A - Theranostic Applications in Prostate Cancer: Current Status and Trends

IAEA Coordinator: Enrique Estrada  
Chairperson: Wim Oyen

09:40-10:00	What are the urologists' needs?	Jochen Walz	Institut Paoli Calmettes Cancer Centre- Marseilles, France	Remote access from France	<ol style="list-style-type: none"> <li>1. Understand the global burden of prostate cancer;</li> <li>2. Assess the needs and expectations of referring physicians when requesting a PET/CT scan;</li> <li>3. Discuss the clinician's perspective in regard to the indications of radionuclide therapies (223 Radium and radiolabelled PSMA).</li> </ol>
10:00-10:20	PSMA and beyond	Stefano Fanti	University of Bologna - Italy	Remote access from Italy	<ol style="list-style-type: none"> <li>1. Review the status of molecular imaging with regards to prostate cancer;</li> <li>2. Discuss new approaches using personalized medicine for prostate cancer;</li> <li>3. Analyse the impact of Ga-PSMA in the management of prostate cancer.</li> </ol>
10:20-10:40	Alpha therapies	Mike Sathekge	University of Pretoria - South Africa	In Vienna	<ol style="list-style-type: none"> <li>1. Recognize the available radionuclide therapies for prostate cancer;</li> <li>2. Analyse the different impacts in patient's overall survival and disease-free survival;</li> <li>3. Discuss the evidence-based data available.</li> </ol>
10:40-12:10	Case review interactive session	Wim Oyen Mike Sathekge	Humanitas Milan - Italy University of Pretoria - South Africa	In Vienna	<ol style="list-style-type: none"> <li>1. Practice relevant case scenarios;</li> <li>2. Reconcile clinical knowledge with novel theranostic methods;</li> <li>3. Demonstrate the role of theranostics in the management of prostate cancer.</li> </ol>
12:10-12:30	Q&A				

### Welcome Remarks

IAEA Coordinator: Diana Paez  
Masters of Ceremony: Sugitha Sureshkumar

12:30-12:40	Welcome Remarks	iViCT Team	International Atomic Energy Agency	In Vienna	
-------------	-----------------	------------	------------------------------------	-----------	--

### Session II - Current Status in the Management of Patients with DTC

IAEA Coordinator: Diana Paez  
Chairperson: Marcus Luster

13:00-13:20	The use of I-131 in DTC: Is there a right answer?	Markus Luster	University of Marburg - Germany	In Vienna	<ol style="list-style-type: none"> <li>1. Analyse the different approaches in the management of a patient with DTC;</li> <li>2. Discuss the appropriate uses of I-131 in patient management;</li> <li>3. Review the challenges for administration of I-131.</li> </ol>
13:20-14:45	International Panel	Mike Sathekge Irene Virgolini Siroos Mirzaei	University of Pretoria - South Africa University of Innsbruck - Austria Wilhelminen Hospital - Austria	In Vienna	<ol style="list-style-type: none"> <li>1. Discuss the multidisciplinary approach of DTC management;</li> <li>2. Discuss the controversies surrounding using of I-131 in DTC treatment;</li> <li>3. Analyse and recognise the new risk stratification system proposed by clinicians.</li> </ol>
		20 panellists	Worldwide		

### Session III-A - Theranostic Applications in Neuroendocrine Tumours: Current Status and Trends

IAEA Coordinator Olivier Pellet  
Chairperson Irene Virgolini

15:00-15:20	What are the clinician's needs?	Francesco Giammarile	International Atomic Energy Agency - Austria	In Vienna	<ol style="list-style-type: none"> <li>1. Describe the global burden of NET;</li> <li>2. Recognize the clinician's perspective in regards to the indications of radionuclide therapies;</li> <li>3. Discuss new approaches using personalized medicine for neuro endocrine neoplasms.</li> </ol>
-------------	---------------------------------	----------------------	--	-----------	--

15:20-15:40	Theranostics: the present (agonist)	Lisa Bodei	Memorial Sloan Kettering Cancer Center - USA	Remote access from USA	<ol style="list-style-type: none"> <li>1. Indicate the status of molecular imaging with regards to NET;</li> <li>2. Analyse the different impacts in patient's overall survival and disease-free survival;</li> <li>3. Discuss the evidence-based data available.</li> </ol>
15:40-16:00	Theranostics: the future (antagonist)	Guillaume Nicolas	University of Basel - Switzerland	In Vienna	<ol style="list-style-type: none"> <li>1. Review the development of radiolabelled somatostatin receptor antagonist for molecular imaging and radionuclide therapy of NET;</li> <li>2. Analyse the differences compared to current imaging and therapy approaches with somatostatin receptor agonist with regard to imaging and therapy outcome;</li> <li>3. Discuss the evidence-based data available.</li> </ol>
16:00-17:30	Case review interactive session	Irene Virgolini	University of Innsbruck - Austria	In Vienna	<ol style="list-style-type: none"> <li>1. Practice relevant case scenarios;</li> <li>2. Reconcile clinical knowledge with novel theranostic methods;</li> <li>3. Demonstrate the role of theranostics in the management of NET.</li> </ol>
17:30-17:50	Q&A				

# iViCT 2019

International Virtual Conference on Theranostics



4–5 September 2019  
**#iViCT2019**

Thursday, 5 September 2019

Time (CEST)	Title	Speaker	Affiliation	Location	Learning Objectives
<b>Session III-B - Theranostic Applications in Neuroendocrine Tumours: Current Status and Trends</b>		<b>IAEA Coordinator: Olivier Pellet Chairperson: Irene Virgolini</b>			
09:30-09:50	What are the clinician's needs?	Francesco Giammarile	International Atomic Energy Agency - Austria	In Vienna	1. Describe the global burden of NET; 2. Recognize the clinician's perspective in regards to the indications of radionuclide therapies; 3. Discuss new approaches using personalized medicine for neuro endocrine neoplasms.
09:50-10:10	Theranostics: the present (agonist)	Lisa Bodei	Memorial Sloan Kettering Cancer Center - USA	Remote access from USA	1. Indicate the status of molecular imaging with regards to NET; 2. Analyse the different impacts in patient's overall survival and disease-free survival; 3. Discuss the evidence-based data available.
10:10-10:30	Theranostics: the future (antagonist)	Guillaume Nicolas	University of Basel - Switzerland	In Vienna	1. Review the development of radiolabelled somatostatin receptor antagonist for molecular imaging and radionuclide therapy of NET; 2. Analyse the differences compared to current imaging and therapy approaches with somatostatin receptor agonist with regard to imaging and therapy outcome; 3. Discuss the evidence-based data available.
10:30-12:00	Case review interactive session	Irene Virgolini	University of Innsbruck - Austria	In Vienna	1. Practice relevant case scenarios; 2. Reconcile clinical knowledge with novel theranostic methods; 3. Demonstrate the role of theranostics in the management of NET.
12:00-12:20	Q&A				
<b>Session IV - Theranostics: The Way Forward</b>		<b>IAEA Coordinator: Diana Paez Chairperson: Marcus Luster</b>			
12:45-13:15	Where we are	Markus Luster	University of Marburg - Germany	In Vienna	1. Discuss new trends in theranostics; 2. Discuss how to disseminate innovative personalized medicine; 3. Discuss the economic and public health impact on advancing theranostic approaches.
13:15-13:45	Where are we going?	Giuliano Mariani	University of Pisa - Italy	Remote access from Italy	1. Discuss new trends in theranostics; 2. Discuss how to disseminate innovative personalized medicine; 3. Discuss the economic and public health impact on advancing theranostic approaches.
13:45-14:30	Q&A				
<b>Session I-B - Theranostic Applications in Prostate Cancer: Current Status and Trends</b>		<b>IAEA Coordinator: Enrique Estrada Chairperson: Wim Oyen</b>			
14:45-15:05	What are the urologists' needs?	Jochen Walz	Institut Paoli-Calmette - France	Remote access from France	1. Understand the global burden of prostate cancer; 2. Assess the needs and expectations of referring physicians when requesting a PET/CT scan; 3. Discuss the clinician's perspective in regard to the indications of radionuclide therapies (223 Radium and radiolabelled PSMA).
15:05-15:25	PSMA and beyond	Stefano Fanti	University of Bologna - Italy	Remote access from Italy	1. Review the status of molecular imaging with regards to prostate cancer; 2. Discuss new approaches using personalized medicine for prostate cancer; 3. Analyse the impact of Ga-PSMA in the management of prostate cancer.
15:25-15:45	Alpha therapies	Mike Sathekge	University of Pretoria - South Africa	In Vienna	1. Recognize the available radionuclide therapies for prostate cancer; 2. Analyse the different impacts in patient's overall survival and disease-free survival; 3. Discuss the evidence-based data available.
15:45-17:15	Case review interactive session	Wim Oyen Mike Sathekge	Humanitas Milan - Italy University of Pretoria - South Africa	In Vienna	1. Practice relevant case scenarios; 2. Reconcile clinical knowledge with novel theranostic methods; 3. Demonstrate the role of theranostics in the management of prostate cancer.
17:15-17:35	Q&A				
<b>CLOSING</b>		<b>Diana Paez, IAEA</b>			